Response by Solomon to Letter Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study"

Affiliations

Comment

Scott D Solomon. Circulation. 2019.

. 2019 Jul 9;140(2):e92-e93.

doi: 10.1161/CIRCULATIONAHA.119.040941. Epub 2019 Jul 8.

¹ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA.

No abstract available

Comment on

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Solomon SD, et al. Circulation. 2019 Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831. Circulation. 2019. PMID: 30586695 Clinical Trial.
Letter by González-Costello et al Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-mediated Amyloidosis: Analysis of the APOLLO Study".
González-Costello J, Casasnovas C, Díez-López C. González-Costello J, et al. Circulation. 2019 Jul 9;140(2):e90-e91. doi: 10.1161/CIRCULATIONAHA.119.039645. Epub 2019 Jul 8. Circulation. 2019. PMID: 31283374 No abstract available.